Bristol-Myers Squibb Company (BMY)
Quick ratio
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | US$ in thousands | 10,346,000 | 7,890,000 | 6,293,000 | 9,330,000 | 11,464,000 | 7,514,000 | 8,372,000 | 8,995,000 | 9,123,000 | 7,734,000 | 10,750,000 | 12,369,000 | 13,979,000 | 13,540,000 | 11,024,000 | 10,982,000 | 14,546,000 | 19,435,000 | 19,934,000 | 15,817,000 |
| Short-term investments | US$ in thousands | 802,000 | 892,000 | 953,000 | 902,000 | 1,275,000 | 517,000 | 1,206,000 | 1,181,000 | 1,234,000 | 2,212,000 | 3,531,000 | 4,053,000 | 5,006,000 | 6,001,000 | 5,360,000 | 5,204,000 | 4,737,000 | 4,781,000 | 4,576,000 | 4,472,000 |
| Receivables | US$ in thousands | 10,747,000 | 11,026,000 | 11,423,000 | 10,447,000 | 10,921,000 | 10,304,000 | 10,112,000 | 10,054,000 | 9,886,000 | 9,613,000 | 9,054,000 | 8,511,000 | 9,369,000 | 9,245,000 | 9,017,000 | 8,660,000 | 8,501,000 | 8,062,000 | 7,855,000 | 8,290,000 |
| Total current liabilities | US$ in thousands | 23,774,000 | 22,638,000 | 23,265,000 | 25,822,000 | 22,262,000 | 23,462,000 | 20,150,000 | 19,085,000 | 21,890,000 | 18,930,000 | 20,915,000 | 22,821,000 | 21,868,000 | 21,460,000 | 18,991,000 | 17,330,000 | 19,080,000 | 20,464,000 | 23,421,000 | 19,232,000 |
| Quick ratio | 0.92 | 0.87 | 0.80 | 0.80 | 1.06 | 0.78 | 0.98 | 1.06 | 0.92 | 1.03 | 1.12 | 1.09 | 1.30 | 1.34 | 1.34 | 1.43 | 1.46 | 1.58 | 1.38 | 1.49 |
December 31, 2024 calculation
Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($10,346,000K
+ $802,000K
+ $10,747,000K)
÷ $23,774,000K
= 0.92
The quick ratio of Bristol-Myers Squibb Company has shown fluctuations over the years based on the provided data. The quick ratio measures the company's ability to meet its short-term liabilities with its most liquid assets. A quick ratio above 1 indicates that the company has enough liquid assets to cover its current liabilities.
From March 31, 2020, to September 30, 2021, the quick ratio remained above 1, indicating a healthy liquidity position. However, there was a gradual decline in the quick ratio from December 31, 2021, to December 31, 2022, with the ratio falling below 1, which may raise concerns about the company's ability to cover its short-term obligations.
The quick ratio improved slightly in the following periods, up to March 31, 2023. However, there was a significant drop in the quick ratio by September 30, 2023, to 0.78, indicating potential liquidity challenges during that period. The ratio fluctuated between 0.78 and 1.06 from September 30, 2023, to March 31, 2024, which suggests continued uncertainty regarding the company's liquidity position.
Overall, Bristol-Myers Squibb Company's quick ratio trend indicates varying levels of liquidity over the analyzed periods, with some fluctuations potentially signaling the need for closer monitoring of the company's ability to meet its short-term financial obligations with its readily available assets.
Peer comparison
Dec 31, 2024